Drugs · acquisition-cost intelligence
FLECTOR
diclofenac epolamine· ingredient diclofenacAcetic acid derivatives and related substances· DICLOFENAC EPOLAMINE .013 g/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$5.03
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other diclofenac products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Diclofenac Sodium Delayed Release | $0.06665 | −$4.96 |
| Diclofenac DR | $0.06665 | −$4.96 |
| Aleve Arthritis Pain Gel | $0.08776 | −$4.94 |
| Diclofenac Potassium | $0.09863 | −$4.93 |
| Clofenax | $0.12486 | −$4.90 |
| Diclofenac Sodium | $0.36949 | −$4.66 |
| Diclofenac Sodium | $0.39681 | −$4.63 |
| Diclofenac Sodium Delayed Release | $0.72051 | −$4.30 |
Medicare Part D coverage · CY2026
On 82 plan formularies · typical tier 4
Prior auth 82% · Step therapy 0% · Quantity limit 79% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.